Engineering Pancreatic Cancer Cell CFPAC-1 for Self-destruction

Despite the tremendous effort in the diagnostics of pancreatic cancer, only very few patients can be cured by surgery leading to a 5-year survival rate of only 3%. Immunotherapy for pancreatic cancer provides potential new options for patients with this difficult-to-treat cancer.